SIX4 activates Akt and promotes tumor angiogenesis

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Angiogenesis is crucial for solid tumor progression.
• Hypoxia promotes vascular endothelial growth factors (VEGFs) via hypoxia-inducible factor 1 (HIF-1α).
• Regulation of HIF-1α remains incompletely understood.

Purpose of the Study:

• Investigate the role of Sine Oculis Homeobox Homolog 4 (SIX4) in colorectal cancer (CRC).
• Determine SIX4's impact on tumor growth, angiogenesis, and its regulatory mechanisms.
• Evaluate SIX4 as a potential anti-angiogenic therapeutic target in CRC.

Main Methods:

• Analysis of SIX4 expression in CRC tissues.
• In vitro and in vivo experiments assessing the effects of SIX4 overexpression and knockdown on tumor growth and angiogenesis.
• Investigation of SIX4's interaction with HIF-1α and its regulation of VEGF-A expression.
• Exploration of SIX4's mechanism involving Akt activation.

Main Results:

• SIX4 is upregulated in CRC, with high expression correlating with poor prognosis.
• SIX4 overexpression enhances tumor growth and angiogenesis; SIX4 knockdown inhibits them.
• SIX4 increases VEGF-A expression by coordinating with HIF-1α.
• SIX4 upregulates HIF-1α expression via Akt activation.

Conclusions:

• SIX4 plays a significant role in regulating tumor angiogenesis in CRC.
• SIX4 enhances tumor growth and angiogenesis through the HIF-1α/VEGF-A pathway.
• SIX4 represents a potential novel target for anti-angiogenic therapy in colorectal cancer.